NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR
INDIRECTLY, IN OR INTO THE UNITED
STATES, CANADA,
JAPAN, SOUTH AFRICA OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH
THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.
STOCKHOLM, March 24, 2020 /PRNewswire/ -- The prospectus
relating to the rights issue in IRRAS AB (publ) ("IRRAS" or the
"Company") (Nasdaq First North Premier Growth Market: IRRAS) of
approximately SEK 217 million before
issue costs has today 24 March 2020
been approved and registered by the Swedish Financial Supervisory
Authority, and is available on IRRAS' website www.irras.com,
together with all other information relating to the rights issue.
The prospectus is also available on Carnegie's website
www.carengie.se and Pareto Securities' website www.paretosec.com
and will within a couple of days also be published on the Swedish
Financial Supervisory Authority's prospectus register,
https://fi.se/sv/vara-register/prospektregistret/. The approval of
the Prospectus should not be understood as an endorsement of the
shares. In order to fully understand the potential risks and
rewards associated with the decision to invest in the Offering,
potential investors should read the Prospectus before making an
investment decision.
Advisors
Carnegie Investment Bank is acting as Global Coordinator and
Joint Bookrunner in the transaction while Pareto Securities is
acting as Joint Bookrunner. Setterwalls Advokatbyrå is acting as
legal adviser.
About IRRAS
IRRAS AB is a global medical technology company focused on
delivering innovative medical technologies to our customers and
their patients. IRRAS designs, develops and commercializes products
that improve patient outcomes and decrease the overall cost of care
by addressing complications associated with current treatment
methods in neurocritical care. IRRAS markets and sells its products
to hospitals worldwide through its direct sales organizations in
the U.S. and select European countries and a network of
distribution partners in other markets.
IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in
Munich, Germany, and San Diego, California, USA. For more
information, please visit www.irras.com.
IRRAS AB (publ) shares are traded on Nasdaq First North Premier
Growth Market (ticker: IRRAS). Redeye AB is certified adviser of
the company with email certifiedadviser@redeye.se or phone +46 8
121 576 90.
This information is information that IRRAS is obliged to
disclose pursuant to the EU Market Abuse Regulation. The
information was released for public disclosure, through the agency
of the contact person above, on 24 March
2020 at 13:30 (CET).
Important Information
The release, announcement or distribution of this press release
may, in certain jurisdictions, be subject to restrictions. The
recipients of this press release in jurisdictions where this press
release has been published or distributed shall inform themselves
of and follow such restrictions. The recipient of this press
release is responsible for using this press release, and the
information contained herein, in accordance with applicable rules
in each jurisdiction. This press release does not constitute an
offer, or a solicitation of any offer, to buy or subscribe for any
securities in the Company in any jurisdiction where such offer
would be considered illegal. This press release does not constitute
an offer to sell or an offer to buy or subscribe for shares issued
by the Company in any jurisdiction where such offer or invitation
would be illegal. In a member state within the European Economic
Area ("EEA"), shares referred to in the press release may only be
offered in accordance with applicable exemptions under the
Prospectus Regulation.
This press release does not constitute or form part of an offer
or solicitation to purchase or subscribe for securities in
the United States. The securities
referred to herein may not be sold in the
United States absent registration or an exemption from
registration under the US Securities Act of 1933, as amended (the
"Securities Act"), and may not be offered or sold within
the United States absent
registration or an applicable exemption from, or in a transaction
not subject to, the registration requirements of the Securities
Act. There is no intention to register any securities referred to
herein in the United States or to
make a public offering of the securities in the United States. The information in this
press release may not be announced, published, copied, reproduced
or distributed, directly or indirectly, in whole or in part, within
or into the United States,
Canada, Japan, South
Africa or Australia, or in
any other jurisdiction where such announcement, publication or
distribution of the information would not comply with applicable
laws and regulations or where such actions are subject to legal
restrictions or would require additional registration or other
measures than what is required under Swedish law. Actions taken in
violation of this instruction may constitute a crime against
applicable securities laws and regulations.
In the United Kingdom, this
document and any other materials in relation to the securities
described herein is only being distributed to, and is only directed
at, and any investment or investment activity to which this
document relates is available only to, and will be engaged in only
with, "qualified investors" who are (i) persons having professional
experience in matters relating to investments who fall within the
definition of "investment professionals" in Article 19(5) of the
Financial Services and Markets Act 2000 (Financial Promotion) Order
2005 (the "Order"); or (ii) high net worth entities falling within
Article 49(2)(a) to (d) of the Order (all such persons together
being referred to as "relevant persons"). In the United Kingdom, any investment or investment
activity to which this communication relates is available only to,
and will be engaged in only with, relevant persons. Persons who are
not relevant persons should not take any action on the basis of
this press release and should not act or rely on it.
A prospectus regarding the Rights Issue described in this
release has been published by the Company on 24 March 2020. This release is however not a
prospectus in accordance to the definition in the Prospectus
Regulation. In accordance with article 2
k of the Prospectus Regulation this press release
constitutes an advertisement. Complete information regarding the
Rights Issue can only be obtained through the Prospectus. IRRAS has
not authorized any offer to the public of shares or rights in any
other member state of the EEA. In any EEA Member State, this
communication is only addressed to and is only directed at
qualified investors in that Member State within the meaning of the
Prospectus Regulation. This announcement does not identify or
suggest, or purport to identify or suggest, the risks (direct or
indirect) that may be associated with an investment in the new
shares. Any investment decision in connection with the Rights Issue
must be made on the basis of all publicly available information
relating to the Company and the Company's shares. Such information
has not been independently verified by the Joint Bookrunners. The
Joint Bookrunners are acting for the Company in connection with the
transaction and no one else and will not be responsible to anyone
other than the Company for providing the protections afforded to
its clients nor for giving advice in relation to the transaction or
any other matter referred to herein.
Information to distributors
Solely for the purposes of the product governance requirements
contained within: (a) EU Directive 2014/65/EU on markets in
financial instruments, as amended ("MiFID II"); (b) Articles 9 and
10 of Commission Delegated Directive (EU) 2017/593 supplementing
MiFID II; and (c) local implementing measures (together, the "MiFID
II Product Governance Requirements"), and disclaiming all and any
liability, whether arising in tort, contract or otherwise, which
any "manufacturer" (for the purposes of the MiFID II Product
Governance Requirements) may otherwise have with respect thereto,
the shares in IRRAS have been subject to a product approval
process, which has determined that such shares are: (i) compatible
with an end target market of retail investors and investors who
meet the criteria of professional clients and eligible
counterparties, each as defined in MiFID II; and (ii) eligible for
distribution through all distribution channels as are permitted by
MiFID II (the "Target Market Assessment"). Notwithstanding the
Target Market Assessment, Distributors should note that: the price
of the shares in IRRAS may decline and investors could lose all or
part of their investment; the shares in IRRAS offer no guaranteed
income and no capital protection; and an investment in the shares
in IRRAS is compatible only with investors who do not need a
guaranteed income or capital protection, who (either alone or in
conjunction with an appropriate financial or other adviser) are
capable of evaluating the merits and risks of such an investment
and who have sufficient resources to be able to bear any losses
that may result therefrom. The Target Market Assessment is without
prejudice to the requirements of any contractual, legal or
regulatory selling restrictions in relation to the Rights
Issue.
For the avoidance of doubt, the Target Market Assessment does
not constitute: (a) an assessment of suitability or appropriateness
for the purposes of MiFID II; or (b) a recommendation to any
investor or group of investors to invest in, or purchase, or take
any other action whatsoever with respect to the shares in
IRRAS.
Each distributor is responsible for undertaking its own target
market assessment in respect of the shares in IRRAS and determining
appropriate distribution channels.
For more information, please contact:
Sabina Berlin
CFO
+46 73 951 95 02
sabina.berlin@irras.com
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/irras/r/irras-publishes-prospectus-relating-to-the-rights-issue-of-approximately-sek-217-million,c3067203
The following files are available for download:
https://mb.cision.com/Main/16550/3067203/1216834.pdf
|
Release
|